等待開盤 05-15 09:30:00 美东时间
+0.240
+1.22%
今日重点评级关注:Canaccord Genuity:维持Sagimet Biosciences"买入"评级,目标价从28美元升至49美元;HC Wainwright & Co.:维持Fate Therapeutics"买入"评级,目标价从5美元升至7美元
05-05 11:40
今日重点评级关注:Benchmark:维持史密斯微软件"买入"评级,目标价从2美元升至2.5美元;Citizens:维持DBV Technologies"跑赢大市"评级,目标价从47美元升至55美元
05-04 16:04
Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.
05-01 21:53
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 57.69 percent increase over losses of $(0.26) per share from
05-01 05:17
DBV Technologies press release (DBVT): Q1 GAAP EPS of -$0.11. Cash Position and LiquidityOn March 31, 2026, the Company held $229 million in Cash and Cash Equivalents compared to $194 million of Cash ...
05-01 05:09
In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Se...
04-11 02:45
JPMorgan Chase tops 10% stake in DBV Technologies, holds 10.03% voting rights JPMorgan Chase crossed above 10% stake in DBV Technologies on March 18, 2026. Holding totaled 27,912,104 shares, equal to 10.03% of share capital and voting rights. Disclosure cited an increase in shares held by assimilati
04-02 17:14
今日重点评级关注:花旗:维持Biomea Fusion"买入"评级,目标价从6美元升至7美元;Chardan Capital:维持Hyperion DeFi"买入"评级,目标价从7.75美元升至8.25美元
03-30 11:49
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, visit our analyst ratings page.
03-27 21:47
Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $51 price target.
03-27 20:45